🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "huge turning point" in the fight against drug-resistant strains of the infection, according to scientists.

A Global Challenge

Gonorrhoea infections are increasing worldwide, with figures suggesting more than 82 million instances each year. Notably increased rates are observed in Africa and countries within the World Health Organization's Western Pacific region, which encompasses China and Mongolia to New Zealand. Within England, cases have reached a all-time high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The authorization of fresh medications for gonorrhoea is an critical and opportune step in the face of rising global incidence, escalating drug resistance and the highly restricted available drugs currently available.”

Medical experts are particularly alarmed about the surge in treatment-resistant strains. The World Health Organization has listed it as a "critical concern". Recent surveillance showed that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Receive Approval

Zoliflodacin, alternatively called a brand name, was approved by the American regulatory agency in mid-December for combating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Scientists anticipate that targeted use of this new drug will help hinder the development of resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This medication, which is employed against UTIs, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment stemmed from a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to see it through.

“This approval signifies a significant shift in the treatment of highly resistant gonorrhoea, which up to this point has been evolving faster than antibiotic development.”

Research Study Data and Global Access

As per data published in a major medical journal, zoliflodacin successfully treated over nine in ten of genital gonorrhoea infections. This puts it on an similar efficacy with the current standard treatment, which combines a dual-drug approach. The study involved hundreds of participants from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, GARDP has the rights to register and commercialise the drug in a wide range of regions with limited resources.

Medical professionals directly involved have voiced positive views. Access to a one-pill regimen such as this is hailed as a "revolutionary step" for gonorrhoea control. This is considered crucial to lessen the impact of the illness for patients and to prevent the spread of highly drug-resistant gonorrhoea around the world.